82
70
Growth Score
12 pts
Heat Score
-22 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
187740
Atrium Therapeutics is a clinical-stage biotech company focused on developing precision RNA medicines for rare genetic cardiomyopathies.
- Kathleen Gallagher: CEO, President, & Board MemberPast Role: Avidity Biosciences, Chief Program Officer
- Steve Hughes: Chief Medical Officer
About the Company
Atrium Therapeutics is a clinical-stage biotechnology company developing precision RNA medicines for rare genetic cardiomyopathies. It specializes in targeted, non-viral delivery of small interfering RNA (siRNA) directly to heart muscle, building on Avidity Biosciences' Antibody Oligonucleotide Conjugate (AOC) platform to overcome non-specific
tissue challenges.
